哈药集团充分发挥企业自身的比较优势,在中国医药企业中,率先将抗生素原料药打入俄国市场,扩大对外贸出口,企业国际竞争力显著增强。自2003年哈药集团的主导产品头孢唑林钠取得俄罗斯国家卫生部颁发的注册证以来,已累计对俄出口抗生素创汇1000余万美元。2005年1~8月,对俄罗斯出 Harbin Pharmaceutical Group gave full play to its own comparative advantages. Among Chinese pharmaceutical enterprises, Harbin Pharmaceutical Group spearheaded the introduction of antibiotic APIs into the Russian market and expanded exports to foreign countries. The international competitiveness of the enterprises was significantly enhanced. Since 2003, the leading product of Harbin Pharmaceutical Group, Cefazolin sodium has obtained the registration certificate issued by the Ministry of Health of Russia. The cumulative export volume of antibiotics in Russia has reached over 10 million U.S. dollars. From January to August 2005, the Russian out